Drugs / Interferon beta-1a
Interferon beta-1a
also known as
Avonex · Rebif · IFN-β-1a · IFN beta - 1a · SNG001 · IFNb-1a · IFN-ß-1a · Interferon β1a · +15 more
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | REBIF | — | 2003-05-02 – 2020-05-26 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | AVONEX | — | 2002-11-12 – 2020-03-27 | fda.gov ↗ |
| Approved | EU (EMA) | Avonex | — | 1997-03-13 | europa.eu ↗ |
| Approved | US (FDA) | AVONEX | — | 1996-05-17 | fda.gov ↗ |
Trials 59
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT04183491 | Feb 2020 → Jan 2021 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT03614715 | Nov 2017 → Feb 2019 | — | Cinnagen | Completed | No outcome recorded |
| Phase 1 | NCT02364986 | Jan 2015 → Jan 2017 | relapsing-remitting multiple sclerosis | PD Dr. Marcus Müller | Unknown | No outcome recorded |
| Phase 1 | NCT02269930 | Oct → Dec 2014 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01766024 | Feb → Jun 2013 | — | Biocad | Completed | No outcome recorded |
| Phase 1 | NCT01416207 | Aug → Oct 2011 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01119677 | May → Oct 2010 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02515695 | May → Jul 2005 | relapsing-remitting multiple sclerosis | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT00097318 | Nov 2004 → Apr 2011 | cerebral infarction | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 1 | NCT01863069 | Jan → Oct 2001 | multiple sclerosis | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05936229 | Apr 2025 → Oct 2027 | B-cell acute lymphoblastic leukemia, mantle cell lymphoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 214 trials · 1 met primary · 7 missed | ||||||
| Phase 2 | NCT06999603 | Sep 2025 → Mar 2026 | viral pneumonia | Synairgen Research Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04521400 | Aug → Sep 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | Missed primary |
| Phase 2 | NCT04343768 | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Completed | Met primary |
| Phase 2 | NCT03119701 | Feb 2017 → Sep 2019 | multiple organ dysfunction syndrome | Faron Pharmaceuticals Ltd | Terminated | Missed primary |
| Phase 2 | NCT02491684 | Jul 2015 → Nov 2016 | asthma | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT01126177 | Mar 2010 → Oct 2011 | asthma | Synairgen Research Ltd. | Completed | Missed primary |
| Phase 2 | NCT00616434 | May 2008 → Mar 2010 | ulcerative colitis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT01075763 | Nov 2004 → May 2008 | Alzheimer disease | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 2 | NCT00099489 | Feb 2004 → Feb 2006 | chronic inflammatory demyelinating polyradiculoneuropathy | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT00912860 | Jan 2003 → Dec 2004 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT00048347 | Oct 2002 → Jun 2008 | ulcerative colitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00303381 | Dec 2001 → Jan 2003 | ulcerative colitis | EMD Serono | Completed | Missed primary |
| Phase 2 | NCT00304252 | Nov 2001 → Sep 2003 | Crohn disease | EMD Serono | Terminated | Missed primary |
| Phase 2 | NCT00001785 | Sep 1998 → Sep 2004 | spinal cord disorder, tropical spastic paraparesis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04518410 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 311 trials · 2 met primary · 3 missed | ||||||
| Phase 3 | NCT04492475 | Aug → Dec 2020 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 3 | NCT04315948 | Mar 2020 → Jul 2022 | COVID-19 | French National Institute of Health and Medical Research | Completed | Missed primary |
| Phase 3 | NCT04032158 | Aug 2019 → Apr 2020 | relapsing-remitting multiple sclerosis | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05242133 | Dec 2017 → Apr 2022 | relapsing-remitting multiple sclerosis | Cinnagen | Completed | Met primary |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02622724 | Dec 2015 → May 2018 | adult acute respiratory distress syndrome | Faron Pharmaceuticals Ltd | Terminated | Missed primary |
| Phase 3 | NCT02937285 | Dec 2010 → May 2020 | multiple sclerosis | Rennes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01181115 | Apr 2010 → Oct 2011 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT00287079 | Oct 2005 → Nov 2008 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00110396 | Jan 2005 → Apr 2007 | multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 3 | NCT00249860 | Sep 2002 → Aug 2005 | chronic hepatitis C virus infection | EMD Serono | Completed | Met primary |
| Phase 420 trials · 2 met primary · 3 missed | ||||||
| Phase 4 | NCT04350671 | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT03535298 | Jan 2019 → Jul 2027 expected | relapsing-remitting multiple sclerosis | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02254304 | Dec 2014 → Aug 2016 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT02117050 | Jun 2014 → Apr 2015 | multiple sclerosis | EMD Serono | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02064816 | May 2014 → Apr 2016 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 4 | NCT01216072 | Aug 2010 → Aug 2012 | multiple sclerosis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT00771043 | Nov 2008 → Aug 2009 | relapsing-remitting multiple sclerosis | Biogen | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT00574041 | Jun 2007 → Feb 2008 | relapsing-remitting multiple sclerosis | Biogen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01142466 | Dec 2005 → Dec 2009 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 4 | NCT00101959 | Nov 2004 → ? | relapsing-remitting multiple sclerosis | EMD Serono | Withdrawn | No outcome recorded |
| Phase 4 | NCT00493077 | May 2004 → May 2006 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00078338 | Feb 2004 → Nov 2006 | relapsing-remitting multiple sclerosis | EMD Serono | Completed | Missed primary |
| Phase 4 | NCT00493116 | Oct 2003 → Dec 2009 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00492466 | Mar 2003 → Aug 2006 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00913666 | Nov 2002 → Nov 2004 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00037115 | May → Dec 2002 | multiple sclerosis, myelitis, neuritis, optic neuritis | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT00037102 | Jul 2001 → Dec 2003 | multiple sclerosis | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Completed | No outcome recorded |
| Phase 4 | NCT00179478 | Feb 2001 → Mar 2009 | cerebelloparenchymal disorder, multiple sclerosis, optic neuritis, transverse myelitis | Beth Israel Deaconess Medical Center | Completed | Met primary |
| Phase 4 | NCT00534261 | Nov 1999 → Feb 2004 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT00915460 | Sep 1999 → Jun 2003 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05024006 | Apr 2020 → Apr 2021 | COVID-19 | University of the Philippines | Completed | No outcome recorded |
| — | NCT00137176 | Oct 2004 → Oct 2007 | multiple sclerosis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Comparator or background therapy59 trials | ||||||
| Phase 1 | NCT02359877 Comparator | Jul 2014 → Oct 2015 | — | Biocad | Completed | No outcome recorded |
| Phase 1 | NCT01074593 Comparator | Jan → Mar 2011 | — | Azidus Brasil | Completed | No outcome recorded |
| Phase 1 | NCT02517788 Comparator | May → Jul 2006 | relapsing-remitting multiple sclerosis | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 2 | NCT06019130 Background | Jan 2023 → Jan 2026 overdue | nasopharyngeal carcinoma | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT05298670 Background | Feb 2022 → Feb 2023 | multiple sclerosis | German University in Cairo | Unknown | No outcome recorded |
| Phase 2 | NCT04385095 Comparator | Mar 2020 → Feb 2021 | COVID-19 | Synairgen Research Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03570359 Comparator | Jan 2018 → May 2020 | chronic obstructive pulmonary disease | Synairgen Research Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01864148 Background | Aug 2013 → Dec 2015 | multiple sclerosis | Biogen | Completed | Missed primary |
| Phase 2 | NCT01285401 Background | Feb 2011 → Apr 2015 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 2 | NCT01071083 Comparator | Mar 2010 → Nov 2011 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT01198132 Background | Nov 2009 → Mar 2015 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00676715 Comparator | Jul 2008 → Mar 2012 | relapsing-remitting multiple sclerosis | Genentech, Inc. | Completed | Met primary |
| Phase 2 | NCT00489489 Background | May 2007 → Jun 2009 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00436826 Background | Nov 2006 → Sep 2011 | multiple sclerosis | EMD Serono Research & Development Institute, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00501943 Comparator | Jul 2006 → Oct 2012 | multiple sclerosis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00273364 Comparator | Nov 2005 → Jan 2017 | multiple sclerosis | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00217295 Background | Apr 2004 → Dec 2007 | multiple sclerosis | Multiple Sclerosis Institute | Unknown | No outcome recorded |
| Phase 2 | NCT00050778 Comparator | Dec 2002 → Sep 2007 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Completed | Met primary |
| Phase 2 | NCT00151801 Background | May 2002 → Dec 2008 | multiple sclerosis | S. Andrea Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01714089 Comparator | — | relapsing-remitting multiple sclerosis | Revalesio Corporation | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02744222 Comparator | Aug 2017 → Nov 2018 | relapsing-remitting multiple sclerosis | Biocad | Completed | No outcome recorded |
| Phase 2/3 | NCT02727907 Comparator | Feb 2015 → Nov 2016 | multiple sclerosis | Biocad | Completed | No outcome recorded |
| Phase 3 | NCT04647669 Comparator | Jun → Nov 2021 | COVID-19 | The University of The West Indies | Unknown | No outcome recorded |
| Phase 3 | NCT04732949 Comparator | Jan → Dec 2021 | COVID-19 | Synairgen Research Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04032171 Comparator | Sep 2019 → May 2020 | relapsing-remitting multiple sclerosis | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02294058 Comparator | Dec 2014 → Dec 2016 | multiple sclerosis | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT01975298 Comparator | Jan → Mar 2014 | relapsing-remitting multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02047734 Comparator | Dec 2013 → Mar 2017 | relapsing-remitting multiple sclerosis | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT01892722 Comparator | Jul 2013 → Jul 2017 overdue | multiple sclerosis | Novartis Pharmaceuticals | Active not recruiting | Met primary |
| Phase 3 | NCT01412333 Comparator | Sep 2011 → May 2015 | multiple sclerosis | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT01247324 Comparator | Aug 2011 → Apr 2015 | multiple sclerosis | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT01064401 Comparator | May 2010 → Mar 2014 | relapsing-remitting multiple sclerosis | Biogen | Completed | Met primary |
| Phase 3 | NCT01058005 Comparator | Mar 2010 → Apr 2012 | relapsing-remitting multiple sclerosis | Biogen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00725985 Background | Dec 2008 → Jul 2011 | multiple sclerosis | EMD Serono Research & Development Institute, Inc. | Completed | Met primary |
| Phase 3 | NCT00605215 Comparator | Apr 2008 → Jun 2011 | multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Missed primary |
| Phase 3 | NCT00548405 Comparator | Oct 2007 → Sep 2011 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00530348 Comparator | Aug 2007 → Apr 2011 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Completed | Mixed |
| Phase 3 | NCT00619307 Comparator | Jul 2007 → Apr 2008 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00472797 Comparator | Apr 2007 → Feb 2009 | multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 3 | NCT00441103 Comparator | Dec 2006 → Nov 2008 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00915577 Background | Aug 2005 → Apr 2006 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT00211887 Comparator | Jan 2005 → Apr 2012 | relapsing-remitting multiple sclerosis | Fred Lublin | Completed | No outcome recorded |
| Phase 3 | NCT00292266 Comparator | Nov 1999 → Jun 2002 | relapsing-remitting multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 4 | NCT03177083 Comparator | Jan 2017 → Oct 2020 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT02234869 Comparator | Oct 2014 → Feb 2017 | multiple sclerosis | Biogen | Withdrawn | No outcome recorded |
| Phase 4 | NCT01791244 Background | Feb 2013 → Feb 2016 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01623596 Comparator | Jun 2012 → Jul 2015 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01534182 Comparator | Jan 2012 → Jun 2013 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01317004 Comparator | May 2011 → Jun 2014 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01085318 Comparator | Jun 2010 → Feb 2012 | multiple sclerosis | EMD Serono | Completed | No outcome recorded |
| Phase 4 | NCT00317941 Comparator | Mar 2006 → Apr 2008 | relapsing-remitting multiple sclerosis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00492765 Background | Feb 2006 → Apr 2010 | multiple sclerosis | Biogen | Completed | Missed primary |
| Phase 4 | NCT01201343 Background | Jan 2005 → Jul 2010 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00146068 Background | Sep 2004 → Dec 2007 | multiple sclerosis | University of North Carolina | Completed | No outcome recorded |
| Phase 4 | NCT00202995 Comparator | Jul 2004 → Oct 2007 | relapsing-remitting multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00246324 Background | Dec 2003 → Aug 2009 | multiple sclerosis | Louisiana State University Health Sciences Center Shreveport | Completed | No outcome recorded |
| Phase 4 | NCT00206648 Comparator | Mar 2003 → Oct 2005 | relapsing-remitting multiple sclerosis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00168766 Background | Jan 2003 → Nov 2008 | relapsing-remitting multiple sclerosis | Biogen | Completed | Missed primary |
| — | NCT01641120 Background | May 2012 → Feb 2014 | multiple sclerosis | Trinity Health Of New England | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 68
| Date | Issuer | Release |
|---|---|---|
| 2026-07-07 | Synairgen Research Ltd. | Results Synairgen Corporate Update synairgen.com ↗
In summary, given that only 11 patients were dosed in the study (and these patients were randomised to receive either low dose SNG001 or placebo in the initial safety cohort), it is not possible to draw any firm conclusions. |
| 2022-12-23 | Synairgen Research Ltd. | Results SPRINTER Trial Results Published synairgen.com ↗
Topline results from this global, double-blind, placebo-controlled trial were first shared in February 2022, with the data analysis presented at the American Thoracic Society International Conference in San Francisco in May 2022. |
| 2022-10-26 | Biogen | Results New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS biogen.com ↗
Data on interferon exposure during pregnancy showed that treatment with PLEGRIDY ® (peginterferon beta-1a) or AVONEX ® (interferon beta-1a) did not negatively impact child development |
| 2022-10-04 | Synairgen Research Ltd. | Results Data from the US NIH-led ACTIV-2 Phase 2 trial synairgen.com ↗
Fewer participants required hospitalisation following treatment with SNG001 (N=1/110, [1%]) compared to placebo (N=7/110, [6%]), an 86% relative risk reduction, that was not statistically significant (P=0.07; two-sided Fisher's exact test). |
| 2022-09-20 | Synairgen Research Ltd. | Results SPRINTER Long COVID data presented at IDWeek synairgen.com ↗
The analysis shows that when compared to placebo, SNG001 reduced the relative risk of recognised symptoms of Long COVID at day 60 and/or day 90: |
| 2022-09-13 | Faron Pharmaceuticals Ltd | Results Traumakine Data Presented at MHSR Symposium faron.com ↗
Primates treated with Traumakine at the time of major inflammation due to ischemia showed lower levels of muscle and liver damage markers indicating total body protection |
| 2022-09-07 | Synairgen Research Ltd. | Results Positive Findings from SG015 Trial Analysis synairgen.com ↗
The results suggest that HRV was cleared more rapidly in patients treated with SNG001 than placebo with a statistically significant difference in the proportion of patients with detectable HRV in sputum at Day 7 ( post hoc analysis). |
| 2022-05-16 | Synairgen Research Ltd. | Results Synairgen presents at ATS 2022 synairgen.com ↗
Post hoc analyses conducted in patient populations at greater risk of progression to severe disease or death suggests that SNG001 may have an important clinical effect on top of standard of care |
| 2022-03-14 | Faron Pharmaceuticals Ltd | Results Faron Publishes Research From INTEREST Trial faron.com ↗
A post hoc genetic analysis by the Company found that patients receiving Traumakine and carrying the SNP rs9984273 (C/T) in subunit 2 of INFAR2 showed a substantial reduction in mortality compared to patients without the gene mutation. |
| 2022-02-21 | Synairgen Research Ltd. | Results Topline results from Phase 3 SPRINTER trial synairgen.com ↗ |
| 2022-02-03 | Faron Pharmaceuticals Ltd | Results Scientific Reports Publishes INFORAAA Results faron.com ↗
today announces that the multidisciplinary journal Scientific Reports from the Nature Publishing Group published research highlighting results from Faron’s Phase II INFORAAA clinical trial. |
| 2021-12-08 | Synairgen Research Ltd. | Results ESWI presentation demonstrates interferon beta has potent antiviral activity against SARS-CoV-2 including variants of concern synairgen.com ↗
In vitro data demonstrate antiviral activity of SNG001 against multiple variants of SARS- CoV-2 |
| 2021-10-13 | EMD Serono Research & Development Institute, Inc. | Results New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients emdserono.com ↗
Consistent with previously reported data, MAVENCLAD-treated patients, as well as those treated with interferon beta-1a, who received the Pfizer/BioNTech mRNA COVID-19 vaccine were found to mount a positive serology response (AU/mL >19), similar to that of healthy controls. |
| 2021-05-24 | Synairgen Research Ltd. | Results Results of in vitro studies synairgen.com ↗
today announces results from in vitro studies showing the antiviral activity of SNG001 against two SARS-CoV-2 variants. |
| 2021-04-30 | Synairgen Research Ltd. | Results Home Cohort data of SG016 Phase II trial synairgen.com ↗
today announces results from the Home Cohort of its SG016 Phase II trial of SNG001 in SARS-CoV-2 infected patients and data from the combined analysis of the Hospital and Home Cohorts. |
| 2021-01-26 | Faron Pharmaceuticals Ltd | Regulatory Update on TRAUMAKINE development faron.com ↗ |
| 2020-12-18 | Synairgen Research Ltd. | Regulatory COVID-19 Clinical Programme Update synairgen.com ↗
SNG001 given Fast Track designation and IND cleared by the US FDA |
| 2020-11-13 | Synairgen Research Ltd. | Results Lancet Respiratory Medicine publishes Phase 2 data synairgen.com ↗
SNG001 was shown to be well tolerated and patients who received the drug had greater odds of improvement and recovered more rapidly. |
| 2020-10-16 | Faron Pharmaceuticals Ltd | Results First Results from WHO Solidarity Trial faron.com ↗
The results show that subcutaneous interferon (IFN) beta-1a was found to be safe, but ineffective to reduce overall mortality in hospitalized patients with COVID-19. |
| 2020-09-11 | Biogen | Results New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio biogen.com ↗
Clinical outcomes in people with MS aged 60 or older (n=286), compared to those under 60 (n=729), indicate that PLEGRIDY and AVONEX may provide real-world treatment benefits over two years in both age groups. |
| 2020-09-08 | Synairgen Research Ltd. | Results Positive interim analysis of SNG001 in COPD synairgen.com ↗
Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces positive data from the interim analysis of its exploratory Phase II clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection. |
| 2020-07-20 | Synairgen Research Ltd. | Results Positive results from trial of SNG001 in hospitalised COVID-19 patients synairgen.com ↗
Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients |
| 2020-05-26 | EMD Serono Research & Development Institute, Inc. | Regulatory Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS emdserono.com ↗ |
| 2020-05-20 | Faron Pharmaceuticals Ltd | Results Faron Pharmaceuticals Oy Harmful association of glucocorticoids in interferon beta-1a treated patients published in Intensive Care Medicine faron.com ↗
The results showed that the desired mechanism of action of IV IFN beta-1a in the lung vasculature – the upregulation of CD73 – is blocked by the administration of glucocorticoids. |
| 2020-04-30 | Synairgen Research Ltd. | Regulatory Approval received to extend SG016 study of SNG001 in COVID-19 to initiate patients in the home environment synairgen.com ↗
Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has received approvals to extend the SG016 trial to patients with SARS -CoV-2 in the home environment. |
| 2020-03-18 | Synairgen Research Ltd. | Regulatory Synairgen to start trial of SNG001 in COVID-19 imminently synairgen.com ↗
Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that it has received expedited approvals from the Medicines and Healthcare products Regulatory Agency ( MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled formulation of interferon -beta-1a) in COVID -19 patients to potentially assist with the global outbreak of the virus. |
| 2019-09-27 | Synairgen Research Ltd. | Results Phase II Biomarker Data for SNG001 to be presented at European Respiratory Society synairgen.com ↗ |
| 2019-09-23 | Biogen | Regulatory Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding biogen.com ↗
Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the of the European Medicines Agency (EMA), recommended an update to marketing authorizations of approved interferon beta treatments, including PLEGRIDY ® (peginterferon beta-1a) and AVONEX ® (interferon beta-1a), to remove pregnancy contraindications and, where clinically needed, to allow use during pregnancy and breastfeeding in women with relapsing multiple sclerosis (MS). |
| 2019-09-12 | Biogen | Results New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum biogen.com ↗
Additional findings confirm exposure to interferon beta, including PLEGRIDY ® (peginterferon beta-1a) and AVONEX ® (interferon beta-1a) , is not expected to impact pregnancy or infant outcomes |
| 2019-06-14 | Faron Pharmaceuticals Ltd | Results Final results from YODA study faron.com ↗
The concomitant use of IFN beta-1a and prednisolone during part III reduced IFN beta-1a action, compared to subjects who received IFN beta-1a alone. |
| 2018-12-05 | Faron Pharmaceuticals Ltd | Results Patient subgroup identified from INTEREST trial faron.com ↗
The D28 overall mortality of this group was 11.1% despite receiving, or not receiving, concurrent steroids. |
| 2018-10-22 | Faron Pharmaceuticals Ltd | Results INTEREST trial update presented at ESICM faron.com ↗ |
| 2018-10-02 | Biogen | Results Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care biogen.com ↗
The European Interferon Beta Pregnancy Registry and Nordic EPID MS Pregnancy Study demonstrated that exposure to interferon beta treatment (including PLEGRIDY and AVONEX) before conception and/or during pregnancy did not adversely affect pregnancy or infant outcomes. |
| 2018-09-12 | Novartis Pharmaceuticals | Results Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS novartis.com ↗
PARADIGMS met the primary endpoint of significantly reducing the rate of relapses when compared to interferon beta-1a intramuscular injections over a period of up to two years[3]. |
| 2018-06-28 | Synairgen Research Ltd. | Results Positive SNG001 Biomarker Data in COPD Patients synairgen.com ↗
Synairgen (LSE: SNG), the respiratory drug discovery and development company, announces positive biomarker data from the ongoing Phase II trial of its antiviral therapy SNG001 in patients suffering from chronic obstructive pulmonary disease (CO PD). |
| 2018-06-22 | Synairgen Research Ltd. | Results Synairgen Safety Data with SNG001 in COPD Patients synairgen.com ↗
COPD is a very severe disease and it is reassuring to establish that SNG001 is well tolerated in these patients. |
| 2018-06-18 | Merck KGaA, Darmstadt, Germany | Results Data Provide Further Insight Into the Consistent Efficacy Benefits of Mavenclad in Relapsing MS prnewswire.com ↗
Furthermore, additional post hoc data from clinical studies of patients treated with Rebif (subcutaneous interferon beta-1a) showed that the MAGNIMS score at Year 1 reliably predicted long-term clinical disease activity (CDA)-free status and disability progression. |
| 2018-06-14 | Faron Pharmaceuticals Ltd | Results Biomarker analysis of Phase III INTEREST trial faron.com ↗ |
| 2018-05-08 | Faron Pharmaceuticals Ltd | Results Top line data from the Phase III INTEREST trial faron.com ↗
The INTEREST study did not meet the Day 28 (D28) primary efficacy composite endpoint of ventilator free days and survival with Traumakine treatment. |
| 2018-01-24 | Faron Pharmaceuticals Ltd | Regulatory FDA approval of Faron’s Traumakine® IND faron.com ↗ |
| 2017-12-27 | Synairgen Research Ltd. | Results Data update from clinical trial of inhaled interferon beta (SNG001) and clinical plan for COPD synairgen.com ↗
Statistically significant changes in morning lung function and asthma control were observed in the virus-positive ‘difficult to treat’ patients who received inhaled IFN-beta; the same patient classification in which we had found the positive signal in our previous Phase II clinical trial (SG005) |
| 2017-10-28 | Novartis Pharmaceuticals | Results Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a novartis.com ↗
Treatment with oral Gilenya resulted in an 82% reduction in the rate of relapses (annualized relapse rate) over a period of up to two years, compared to interferon beta-1a intramuscular injections (p <0.001)[1]. |
| 2017-10-27 | Hoffmann-La Roche | Results New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis roche.com ↗
OCREVUS significantly reduced the proportion of people with RMS who experienced Progression Independent of Relapse Activity (PIRA) in a post-hoc analysis compared to Rebif® (interferon-beta 1a). |
| 2017-09-05 | Novartis Pharmaceuticals | Results Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS novartis.com ↗
Data show that oral fingolimod resulted in a significant and clinically meaningful reduction in the number of relapses (annualized relapse rate) in this patient population over a period of up to two years, compared to interferon beta-1a intramuscular injections[1]. |
| 2017-04-27 | Synairgen Research Ltd. | Results AZD9412 Update synairgen.com ↗
Cold infections did not affect trial patients’ asthma in the INEXAS study as much as predicted, meaning that the drug’s effects on severe exacerbations could not be determined |
| 2017-04-26 | Hoffmann-La Roche | Results New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis roche.com ↗
In patients with early RMS – recently diagnosed and without prior treatment – OCREVUS was superior to Rebif® (interferon beta-1a) in controlling disease activity |
| 2016-10-12 | Synairgen Research Ltd. | Results AZD9412 Clinical Trial Update synairgen.com ↗
AstraZeneca has decided to stop the Ph ase IIa trial for AZD9412 based on an interim analysis, where an overall very low number of reported severe exacerbations could make primary endpoint conclusions difficult. |
| 2016-09-15 | Biogen | Results New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile biogen.com ↗
A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA TM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking AVONEX ® (interferon beta-1a) intramuscular injection. |
| 2016-09-08 | Biogen | Results Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio biogen.com ↗ |
| 2016-04-20 | Biogen | Results Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action biogen.com ↗
New 144-week data show mean improvements from baseline on the Symbol Digit Modalities Test (a measure of visual information processing speed and attention in patients) were +6.30 for ZINBRYTA-treated patients versus +3.09 for AVONEX-treated patients; p=0.0024. |
| 2016-01-07 | Faron Pharmaceuticals Ltd | Results Top-line results from Japanese study of Traumakine faron.com ↗
The all-cause mortality rate at Day 28, being the primary efficacy end point, was 22.2% across all patients (4/18). |
| 2015-10-08 | Biogen | Results Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS biogen.com ↗
Lead investigators on behalf of Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) presented these new findings today at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain (7-10 October). |
| 2015-06-29 | Genentech, Inc. | Results Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis gene.com ↗
Treatment with ocrelizumab significantly reduced the annualized relapse rate (ARR) over a two-year period compared with interferon beta-1a, the primary endpoint in both studies. |
| 2015-04-21 | Novartis Pharmaceuticals | Results Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients novartis.com ↗
Separate analysis from the entire phase III TRANSFORMS study also confirmed that after one year of treatment, RMS patients on Gilenya were twice as likely to achieve NEDA4 compared to patients given Avonex ® * - interferon beta-1a i.m. injections (odds ratio 1.93; 95% CI 1.36-2.73; p=0.0002)[10]. |
| 2014-09-12 | Biogen | Results Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) biogen.com ↗ |
| 2014-06-16 | Biogen | Results Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis biogen.com ↗
Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001). |
| 2013-07-18 | Synairgen Research Ltd. | Results Positive Anti-Inflammatory and Anti-Viral Data synairgen.com ↗
Analysis of these samples now reveals that SNG001 significantly reduced markers of inflammation (IL-8/ CXCL8 and CCL4) as well as increasing anti -viral activity (Mx1, OAS1 and IP -10/CXCL10) in the asthmatic lung during common cold infection s. |
| 2012-04-19 | Synairgen Research Ltd. | Results Positive Phase II asthma clinical trial data synairgen.com ↗
Patients with ‘difficult to treat’ asthma, being approximately half of the patients in the trial, benefitted significantly from SNG001 treatment . |
| 2012-02-28 | Biogen | Regulatory FDA Approves AVONEX® PEN™ and Dose Titration Regimen biogen.com ↗
Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS). |
| 2011-10-11 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with COPAXONE(R) tevapharm.com ↗
In the study, the COPAXONE(R) treatment arm resulted in a -2.27 percent change in brain volume (PCVB) as compared to baseline versus -2.62 percent for Avonex(R) (low-dose interferon), -3.21 percent for Betaseron(R)/Rebif(R) (high-dose interferon). |
| 2011-06-28 | Synairgen Research Ltd. | Results Phase II asthma study – Interim Review and update synairgen.com ↗
The interim review also included a review of blinded safety related data and this data suggested that the drug remains well tolerated. |
| 2011-06-07 | Biogen | Regulatory CORRECTING and REPLACING Biogen Idec Receives Approval in the European Union for AVONEX® PEN™ biogen.com ↗
Biogen Idec (NASDAQ: BIIB) announced today that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event. |
| 2011-06-06 | Biogen | Results CORRECTING and REPLACING Biogen Idec Reports Positive Data from AVONEX Dose Titration Study at 2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers biogen.com ↗
The data demonstrated that dose titration with AVONEX over three weeks at the initiation of treatment resulted in a 76 percent reduction in flu-like symptom severity between pre-injection and the four–six-hour post-injection time point versus no titration ( p <0.001). |
| 2011-04-19 | Biogen | Regulatory Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on AVONEX PEN biogen.com ↗
The company also announced an authorisation for AVONEX PEN from Health Canada. |
| 2010-05-17 | Synairgen Research Ltd. | Results New data for the treatment of “severe‟ influenza lung infection synairgen.com ↗
Data from its new in vitro lung re-infection model shows for the first time that SNG001 can prevent the spread of infection from cell to cell , even after an influenza infection has taken hold. |
| 2009-04-30 | Biogen | Results First Ten-Year Follow-Up Shows That Treatment with AVONEX® Leads to Long-Term Benefits in Early Multiple Sclerosis Patients biogen.com ↗
The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. |
| 2009-04-15 | Biogen | Results Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology biogen.com ↗
Another presentation will include further evidence on the potential mechanism of action of AVONEX ( Interferon-beta Treatment Increases FoxP3 Expression and CD56 bright Natural Killer Cells in Subjects with Multiple Sclerosis – S06.001 ). |
| 2008-09-18 | Biogen | Results New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life biogen.com ↗
Biogen Idec (NASDAQ: BIIB) today announced that data was presented from the ASSURANCE ( ASS essment of Drug U tilization, Ea R ly Tre A tme N t, and C linical Outcom E s) study, showing the long-term benefits of AVONEX ® (interferon beta-1a IM) therapy in patients with relapsing multiple sclerosis (MS) for up to 15 years. |
All press releases naming this drug 84 releases
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 133 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon beta 1a | “Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer...” NCT00273364 ↗93“The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon...” NCT00146068 ↗ “This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in...” NCT02254304 ↗ “The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and a one-time high dose intravenous methotrexate with Leucovorin rescue, along...” NCT00037115 ↗ “RNF (Rebif New Formulation, Merck Serono International S.A., Geneva, Switzerland), a formulation of interferon-beta1a (IFN-beta1a) without human- or animal-derived components,...” PMID 17692727 ↗ Jun 2007 “Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.” PMID 33189161 ↗ Nov 2020 “s.c. interferon beta-1a injected three times per week (Rebif®) have demonstrated efficacy in relapsing-remitting multiple sclerosis” PMID 27060836 ↗ May 2016 “This study will evaluate the safety and effectiveness of the drug interferon-beta1a (AVONEX) in treating ulcerative colitis” NCT00048347 ↗ “Interferon beta-1a (\[IFNB-1a\] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II” NCT00317941 ↗ “Natalizumab (TYSABRI®) or Interferon beta-1a (AVONEX®) treatments initiated at the time of acute optic neuritis (AON)” NCT00771043 ↗ “Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.” PMID 20200197 ↗ Mar 2010 |
| Known as | Avonex | “Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or...” NCT00436826 ↗32“Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer...” NCT00273364 ↗ “The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon...” NCT00146068 ↗ “The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and a one-time high dose intravenous methotrexate with Leucovorin rescue, along...” NCT00037115 ↗ “The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and...” NCT00099489 ↗ “Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)” NCT00001785 ↗ “Immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a first attack of multiple sclerosis (MS)” NCT00179478 ↗ “Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.” NCT01714089 ↗ “Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex)” NCT01623596 ↗ “Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)” NCT05298670 ↗ “Avonex 30 µg IM once per week” NCT00206648 ↗ |
| Known as | Avonex (beta interferon) | “Avonex (beta interferon)” NCT03535298 ↗ |
| Known as | AZD9412 | “OBJECTIVE: To evaluate the efficacy of on-demand inhaled IFN-β1a (AZD9412) to prevent severe asthma exacerbations following symptomatic URTI.” PMID 33091192 ↗ Nov 2020 |
| Known as | BG9418 | “BG9418 (Interferon beta-1a)” NCT00616434 ↗ |
| Known as | FP-12-lyo | “FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.” NCT03119701 ↗ |
| Known as | FP-1201 | “intravenous interferon-beta-1a (FP-1201) works” NCT05936229 ↗ |
| Known as | IFN | “determine whether combined use of interferon β-1a (IFN) 30 μg intramuscularly weekly and glatiramer acetate (GA) 20 mg daily is more efficacious than either agent alone in...” PMID 23424159 ↗ Mar 2013 |
| Known as | IFN beta - 1a | “The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the...” NCT00287079 ↗5“Mortality remains high after emergency open surgery for a ruptured abdominal aortic aneurysm (RAAA). The aim of the present study was to assess, if intravenous (IV) Interferon...” PMID 35115574 ↗ Feb 2022 “patients with steroid-induced clinical remissions of CD were randomized 1:1:1:1 to subcutaneous IFN beta-1a: 66 mcg three times weekly (tiw), 44 mcg tiw, 44 mcg twice weekly...” PMID 19302707 ↗ Mar 2009 “RNF (Rebif New Formulation, Merck Serono International S.A., Geneva, Switzerland), a formulation of interferon-beta1a (IFN-beta1a) without human- or animal-derived components,...” PMID 17692727 ↗ Jun 2007 “Recombinant human interferon beta-1a (IFN-Beta1a) is an FDA approved treatment for patients with relapsing remitting multiple sclerosis” NCT00097318 ↗ “sc IFN Beta 1a (Rebif®) Administered in the Morning” NCT02064816 ↗ |
| Known as | IFN-ß-1a | “IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe.” NCT04315948 ↗1“IFN-ß-1a 44 Mcg Tiw SC (Rebif®)” NCT00101959 ↗ |
| Known as | IFN-β-1a | “fingolimod administered for up to 2 years significantly reduced the annualised relapse rate (ARR) and rate of new/newly enlarged T2 (n/neT2) lesions compared with interferon (IFN) β-1a.” PMID 31467033 ↗ Aug 20196“Women with relapsing-remitting (RR) MS were randomly assigned (1:1:1) to receive subcutaneous IFN-β-1a (Rebif®, Merck Serono, Geneva, Switzerland) 44 mcg three times a week (tiw)” PMID 27995531 ↗ Feb 2017 “Eligible patients with RRMS treated with SC interferon-β-1a (IFN-β-1a) 44 μg 3 times weekly and serum 25(OH)D levels <150 nmol/L were included.” PMID 31594857 ↗ Oct 2019 “adjuvant therapy to interferon beta 1a (IFNβ-1a) in relapsing-remitting multiple sclerosis (RRMS) patients.” PMID 38070031 ↗ Dec 2023 “interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses” NCT02047734 ↗ “SNG001, IFN-β1a solution for inhalation” NCT01126177 ↗ “High dose IFN-β1a (Recigen)” NCT04521400 ↗ |
| Known as | IFNb-1a | “The primary purpose is to determine the changes in gene expression induced by IFNb-1a (Rebif) and atorvastatin (Lipitor) combination therapy in patients with an isolated...” NCT00137176 ↗2“Interferon beta-1a (\[IFNB-1a\] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II” NCT00317941 ↗ “Interferon beta-1a (IFNB-1a), a FDA approved therapy for relapsing-remitting (RR) MS has several mechanisms of action.” NCT00146068 ↗ |
| Known as | Interferon ß-1a | “Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6” NCT04647669 ↗ |
| Known as | Interferon β1a | “Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine” NCT04350671 ↗1“Interferon β1a(daily injection for 6 days)” NCT04647669 ↗ |
| Known as | Rebif | “Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or...” NCT00436826 ↗26“This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in...” NCT02254304 ↗ “Women with relapsing-remitting (RR) MS were randomly assigned (1:1:1) to receive subcutaneous IFN-β-1a (Rebif®, Merck Serono, Geneva, Switzerland) 44 mcg three times a week (tiw)” PMID 27995531 ↗ Feb 2017 “morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms” NCT02064816 ↗ “Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease” NCT00304252 ↗ “current Rebif (subcutaneously injected interferon beta-1a, 44 mcg three-times-weekly)” NCT00619307 ↗ “Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex)” NCT01623596 ↗ “Rebif or Betaseron/Betaferon” NCT02234869 ↗ “Rebif® (Interferon Beta-1a)” NCT00472797 ↗ “Rebif (beta interferon)” NCT03535298 ↗ |
| Known as | Rebif (beta interferon) | “Rebif (beta interferon)” NCT03535298 ↗ |
| Known as | Rebif (R) | “Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL...” NCT04492475 ↗ |
| Known as | Rebif New Formulation | “human interferon beta 1a - Rebif New Formulation” NCT00472797 ↗1“Rebif® New Formulation (IFN-beta-1a, RNF)” NCT00441103 ↗ |
| Known as | Rebif(Registered Trademark) | “The purpose of this study is to investigate the safety of IFN-Beta1a (Rebif(Registered Trademark)) in patients with acute ischemic stroke.” NCT00097318 ↗ |
| Known as | Rebiff | “Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)” NCT05298670 ↗ |
| Known as | Recigen | “High dose IFN-β1a (Recigen)” NCT04521400 ↗1“Interferon-β 1a (Recigen)” PMID 32493468 ↗ Jun 2020 |
| Known as | Recombinant Human Interferon Beta-1a | “A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery...” NCT03119701 ↗ |
| Known as | RNF | “received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks.” NCT00725985 ↗1“Rebif® New Formulation (IFN-beta-1a, RNF)” NCT00441103 ↗ |
| Known as | SNG001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04518410 ↗ |
| Action | Inhibit | “Studies have shown that interferon-beta may block the activity of these cytokines.” NCT00048347 ↗ |
| Modality | Protein / enzyme biologic | “Human interferon is a small protein released from different kinds of cells in the body.” NCT00001785 ↗ |
| Route | Intramuscular | “weekly intramuscular treatment with AVONEX® (interferon beta 1-a)” NCT00037102 ↗ |